|Articles|April 28, 2020
Dr. Thrasher discusses COVID-19's impact on the ABU, telemedicine, research
J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.
Advertisement
The COVID-19 pandemic presents myriad challenges for urologists, including the implementation of telemedicine, protecting staff and patients, and the postponement of elective procedures. The pandemic’s effect is felt even in the area of recertification. On April 2, J. Brantley Thrasher, MD, executive director of the American Board of Urology, spoke with Urology Times about what the ABU is doing to reduce the burden on urologists and their practice.
Also see:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5







